Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Connect Biopharma Holdings LtdCNTB · Entity 6516 | Director | September 30, 2026 | October 02, 2026 |
| Erasca, Inc.ERAS · Entity 3796 | Director | June 26, 2026 | June 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Connect Biopharma Holdings Ltd
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 20,763 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 8,984 · Balance 20,763 F1: In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Ms. Liu elected to receive fully vested shares in lieu of cash compensation for her 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Ms. Liu for her service as a director during the third quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares for the 30 days preceding September 30, 2026, rounded down to the nearest whole share. |
Filing footnotes · ownership attribution and instrument terms
F1: In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Ms. Liu elected to receive fully vested shares in lieu of cash compensation for her 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Ms. Liu for her service as a director during the third quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares for the 30 days preceding September 30, 2026, rounded down to the nearest whole share.
Erasca, Inc.
Report date June 26, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.01 · Expires 2036-06-26 | Direct | 29,888 |
Reported balance
After 2026-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 29,888 · Balance 29,888 F1: 100% of the options to purchase shares vest on June 26, 2027, subject to the Reporting Person's continuous service to the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the options to purchase shares vest on June 26, 2027, subject to the Reporting Person's continuous service to the Issuer on such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Seagen Inc.
Report date December 14, 2023 · Filed December 15, 2023
Section 16 reporting ended · disclosed 2023-12-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 1
1 source rowRow 1 · 2023-12-14 · Disposition to issuer · Disposed 48,748 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration"). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.15 · Expires 2025-08-25 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-12-14 · Disposition to issuer · Disposed 7,446 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.30 · Expires 2026-08-27 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-12-14 · Disposition to issuer · Disposed 35,293 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.37 · Expires 2027-08-17 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-12-14 · Disposition to issuer · Disposed 40,344 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.86 · Expires 2028-08-30 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-12-14 · Disposition to issuer · Disposed 40,523 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.64 · Expires 2029-08-30 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-12-14 · Disposition to issuer · Disposed 1,333 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.64 · Expires 2029-08-30 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-12-14 · Disposition to issuer · Disposed 43,786 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $161.82 · Expires 2030-08-17 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-12-14 · Disposition to issuer · Disposed 636 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $161.82 · Expires 2030-08-17 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-12-14 · Disposition to issuer · Disposed 17,205 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $155.87 · Expires 2031-08-16 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-12-14 · Disposition to issuer · Disposed 642 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $155.87 · Expires 2031-08-16 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-12-14 · Disposition to issuer · Disposed 21,915 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2023-12-14 · Disposition to issuer · Disposed 1,798 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a "Company RSU"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2023-12-14 · Disposition to issuer · Disposed 4,622 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a "Company RSU"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2023-12-14 · Disposition to issuer · Disposed 4,436 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a "Company RSU"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2023-12-14 · Disposition to issuer · Disposed 10,298 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a "Company RSU"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2023-12-14 · Disposition to issuer · Disposed 1,389 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2023-12-14 · Disposition to issuer · Disposed 13,107 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2023-12-14 · Disposition to issuer · Disposed 2,708 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2023-12-14 · Disposition to issuer · Disposed 3,662 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2023-12-14 · Disposition to issuer · Disposed 583 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · 2023-12-14 · Disposition to issuer · Disposed 5,554 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · 2023-12-14 · Disposition to issuer · Disposed 9,423 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 23
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 23 · 2023-12-14 · Disposition to issuer · Disposed 12,688 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 24
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 24 · 2023-12-14 · Disposition to issuer · Disposed 1,457 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 25
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 25 · 2023-12-14 · Disposition to issuer · Disposed 874 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 26
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 26 · 2023-12-14 · Disposition to issuer · Disposed 1,305 · Balance 0 F7: Pursuant to the Merger Agreement, at the Effective Time, each outstanding "Company Products PSU" (as defined in the Merger Agreement) that was unvested as of immediately prior to the Effective Time was cancelled and converted into the right to receive a Parent cash-based award subject to the same performance-based vesting requirements with respect to an amount in cash that is equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company Products PSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 27
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 27 · 2023-12-14 · Disposition to issuer · Disposed 1,165 · Balance 0 F8: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a "Company August 2023 PSU") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 28
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 28 · 2023-12-14 · Disposition to issuer · Disposed 2,912 · Balance 0 F8: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a "Company August 2023 PSU") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 29
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 29 · 2023-12-14 · Disposition to issuer · Disposed 1,747 · Balance 0 F8: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a "Company August 2023 PSU") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").
F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration").
F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a "Company RSU"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU.
F5: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU.
F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance.
F7: Pursuant to the Merger Agreement, at the Effective Time, each outstanding "Company Products PSU" (as defined in the Merger Agreement) that was unvested as of immediately prior to the Effective Time was cancelled and converted into the right to receive a Parent cash-based award subject to the same performance-based vesting requirements with respect to an amount in cash that is equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company Products PSU.
F8: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a "Company August 2023 PSU") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 16, 2021 Filed Aug 18, 2021 20:28 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 718 | $154.55 | $110,969.77 |
DisclosureSEC source: 0001203311-21-000061 · edgardoc.xml · nonDerivative · entry 1 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,333 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| May 11, 2021 Filed May 13, 2021 19:17 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 1,061 | $140.00 | $148,540.00 |
DisclosureSEC source: 0001203311-21-000022 · edgardoc.xml · nonDerivative · entry 1 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,051 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 20:48 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 539 | $0.00 Strike: $46.37 | $0.00 |
DisclosureSEC source: 0001203311-21-000012 · edgardoc.xml · derivative · entry 6 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,617 Underlying: Common Stock · 539 shares Expires 2027-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Shares vested at a rate of 25% on 8/17/2018 and monthly thereafter until all the shares are fully vested on 8/17/21. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 20:48 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,207 | $0.00 Strike: $45.30 | $0.00 |
DisclosureSEC source: 0001203311-21-000012 · edgardoc.xml · derivative · entry 5 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,207 shares Expires 2026-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares vested at a rate of 25% on 8/27/2017 and monthly thereafter until all the shares were fully vested on 8/27/20. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 20:48 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,100 | $0.00 Strike: $35.95 | $0.00 |
DisclosureSEC source: 0001203311-21-000012 · edgardoc.xml · derivative · entry 4 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,100 shares Expires 2024-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares vested at a rate of 25% on 11/17/2015 and monthly thereafter until all the shares were fully vested on 11/17/18. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 20:48 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 2,100 | $35.95 | $75,495.00 |
DisclosureSEC source: 0001203311-21-000012 · edgardoc.xml · nonDerivative · entry 3 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 20:48 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 2,207 | $45.30 | $99,977.10 |
DisclosureSEC source: 0001203311-21-000012 · edgardoc.xml · nonDerivative · entry 2 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 20:48 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 539 | $46.37 | $24,993.43 |
DisclosureSEC source: 0001203311-21-000012 · edgardoc.xml · nonDerivative · entry 1 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| January 15, 2021 Filed Jan 15, 2021 19:40 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $35.95 | $0.00 |
DisclosureSEC source: 0001203311-21-000004 · edgardoc.xml · derivative · entry 3 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,876 Underlying: Common Stock · 5,000 shares Expires 2024-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Options vested at a rate of 25% on 11/17/2015 and then monthly thereafter until all shares were fully vested on 11/17/18. Read SEC document |
| January 15, 2021 Filed Jan 15, 2021 19:40 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 5,000 | $180.00 | $900,000.00 |
DisclosureSEC source: 0001203311-21-000004 · edgardoc.xml · nonDerivative · entry 2 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,266 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| January 15, 2021 Filed Jan 15, 2021 19:40 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 5,000 | $35.95 | $179,750.00 |
DisclosureSEC source: 0001203311-21-000004 · edgardoc.xml · nonDerivative · entry 1 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,266 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2020 Filed Dec 16, 2020 19:41 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 1,624 | $0.00 Strike: $35.95 | $0.00 |
DisclosureSEC source: 0001203311-20-000142 · edgardoc.xml · derivative · entry 8 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,100 Underlying: Common Stock · 1,624 shares Expires 2024-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Options vested at a rate of 25% on 11/17/15 and then monthly thereafter until all options were fully vested on 11/17/18. Read SEC document |
| December 16, 2020 Filed Dec 16, 2020 19:41 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 1,624 | $35.95 | $58,382.80 |
DisclosureSEC source: 0001203311-20-000142 · edgardoc.xml · nonDerivative · entry 7 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,266 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 19:41 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $35.95 | $0.00 |
DisclosureSEC source: 0001203311-20-000142 · edgardoc.xml · derivative · entry 9 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,876 Underlying: Common Stock · 5,000 shares Expires 2024-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Options vested at a rate of 25% on 11/17/15 and then monthly thereafter until all options were fully vested on 11/17/18. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 19:41 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 937 | $198.17 | $185,685.29 |
DisclosureSEC source: 0001203311-20-000142 · edgardoc.xml · nonDerivative · entry 6 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,642 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $197.98 to $198.40. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 19:41 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 1,522 | $197.14 | $300,047.08 |
DisclosureSEC source: 0001203311-20-000142 · edgardoc.xml · nonDerivative · entry 5 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,579 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $196.91 to $197.89. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 19:41 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 300 | $196.03 | $58,809.00 |
DisclosureSEC source: 0001203311-20-000142 · edgardoc.xml · nonDerivative · entry 4 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,101 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $195.77 to $196.54. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 19:41 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 600 | $194.80 | $116,880.00 |
DisclosureSEC source: 0001203311-20-000142 · edgardoc.xml · nonDerivative · entry 3 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,401 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $194.51 to $194.95. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 19:41 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 1,641 | $193.72 | $317,894.52 |
DisclosureSEC source: 0001203311-20-000142 · edgardoc.xml · nonDerivative · entry 2 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,001 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $193.31 to $194.06. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 19:41 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 5,000 | $35.95 | $179,750.00 |
DisclosureSEC source: 0001203311-20-000142 · edgardoc.xml · nonDerivative · entry 1 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,642 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 19:28 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,554 | $0.00 Strike: $39.15 | $0.00 |
DisclosureSEC source: 0001203311-20-000115 · edgardoc.xml · derivative · entry 4 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,554 shares Expires 2025-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares vested at a rate of 25% on 8/25/2016 and monthly thereafter until all the shares were fully vested on 8/25/19. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 19:28 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 7,400 | $0.00 Strike: $35.95 | $0.00 |
DisclosureSEC source: 0001203311-20-000115 · edgardoc.xml · derivative · entry 3 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,724 Underlying: Common Stock · 7,400 shares Expires 2024-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares vested at a rate of 25% on 11/17/2015 and monthly thereafter until all the shares were fully vested on 11/17/18. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 19:28 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 7,400 | $35.95 | $266,030.00 |
DisclosureSEC source: 0001203311-20-000115 · edgardoc.xml · nonDerivative · entry 2 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,642 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 19:28 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 2,554 | $39.15 | $99,989.10 |
DisclosureSEC source: 0001203311-20-000115 · edgardoc.xml · nonDerivative · entry 1 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 18:53 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 11,610 | $170.00 | $1,973,700.00 |
DisclosureSEC source: 0001203311-20-000113 · edgardoc.xml · nonDerivative · entry 1 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,688 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 19:25 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 1,893 | $155.69 | $294,729.12 |
DisclosureSEC source: 0001203311-20-000102 · edgardoc.xml · nonDerivative · entry 2 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,298 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 19:25 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 1,755 | $155.69 | $273,243.32 |
DisclosureSEC source: 0001203311-20-000102 · edgardoc.xml · nonDerivative · entry 1 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,191 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 18:58 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 6,846 | $158.17 | $1,082,822.92 |
DisclosureSEC source: 0001203311-20-000090 · edgardoc.xml · nonDerivative · entry 1 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,946 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 17, 2020 Filed Aug 17, 2020 21:27 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 17,205 | $0.00 Strike: $161.82 | $0.00 |
DisclosureSEC source: 0000899243-20-022632 · doc4.xml · derivative · entry 3 LIU JEAN I · CIK 0001241357 · GC/EVP, Legal Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,205 Underlying: Common Stock · 17,205 shares Expires 2030-08-17 F4 · derivative.exercise_date: Options shall vest at a rate of 25% one year from grant date and monthly thereafter until all shares are fully vested four years from grant date. Read SEC document |
| August 17, 2020 Filed Aug 17, 2020 21:27 UTC | Seagen Inc. SGEN · Entity 13956 | GrantIncentive Stock Option (right to buy) · Derivative | 636 | $0.00 Strike: $161.82 | $0.00 |
DisclosureSEC source: 0000899243-20-022632 · doc4.xml · derivative · entry 2 LIU JEAN I · CIK 0001241357 · GC/EVP, Legal Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 636 Underlying: Common Stock · 636 shares Expires 2030-08-17 F4 · derivative.exercise_date: Options shall vest at a rate of 25% one year from grant date and monthly thereafter until all shares are fully vested four years from grant date. Read SEC document |
| August 17, 2020 Filed Aug 17, 2020 21:27 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 7,195 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022632 · doc4.xml · nonDerivative · entry 1 LIU JEAN I · CIK 0001241357 · GC/EVP, Legal Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,792 F1 · security: These shares represent restricted stock units and will be settled in common stock upon vesting. F2 · date: Shares shall vest at a rate of 25% on each anniversary of August 15, 2020 until all shares are fully vested at the end of four years. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| June 19, 2020 Filed Jun 22, 2020 19:46 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 9,877 | $165.00 | $1,629,705.00 |
DisclosureSEC source: 0001203311-20-000060 · edgardoc.xml · nonDerivative · entry 1 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,597 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| April 19, 2020 Filed Apr 22, 2020 06:11 UTC | Seagen Inc. SGEN · Entity 13956 | Disposition to issuerCommon Stock | 645 | $139.92 | $90,246.40 |
DisclosureSEC source: 0000899243-20-011132 · doc4.xml · nonDerivative · entry 3 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Afairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,474 F4 · shares: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F5 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| April 19, 2020 Filed Apr 22, 2020 06:11 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 1,028 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-011132 · doc4.xml · nonDerivative · entry 2 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Afairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,119 F1 · security: These shares represent restricted stock units and will be settled in common stock upon vesting. F3 · shares: The performance criteria for these restricted stock units were met. These restricted stock units will become fully vested on 4/19/2022, subject to continuous service with the Company until the vesting date. Read SEC document |
| April 19, 2020 Filed Apr 22, 2020 06:11 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 1,706 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-011132 · doc4.xml · nonDerivative · entry 1 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Afairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,091 F2 · shares: The performance criteria for these restricted stock units were met. These restricted stock units became fully vested on 4/19/2020. Read SEC document |
| December 19, 2019 Filed Dec 23, 2019 17:18 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 697 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-029966 · doc4.xml · nonDerivative · entry 1 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Afairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,385 F1 · security: These shares represent restricted stock units that will be settled in common stock upon vesting. F2 · date: The performance criteria for these restricted stock units were met. These restricted stock units will become fully vested on 12/18/2021, subject to continuous service with the Company until the vesting date. F3 · balance_after: Amount of securities beneficially owned following the reported transactions includes restricted stock units subject to vesting. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 18:10 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 3,716 | $85.00 | $315,860.00 |
DisclosureSEC source: 0001203311-19-000049 · edgardoc.xml · nonDerivative · entry 2 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,688 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 18:10 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 3,716 | $87.00 | $323,292.00 |
DisclosureSEC source: 0001203311-19-000049 · edgardoc.xml · nonDerivative · entry 1 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,404 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 21:42 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 1,779 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-022786 · doc4.xml · nonDerivative · entry 2 LIU JEAN I · CIK 0001241357 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,120 F4 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 21:42 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon. Qualified Stock Option (right to buy) · Derivative | 43,786 | $0.00 Strike: $72.64 | $0.00 |
DisclosureSEC source: 0000899243-19-022786 · doc4.xml · derivative · entry 4 LIU JEAN I · CIK 0001241357 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,786 Underlying: Common Stock · 43,786 shares Expires 2029-08-30 F5 · derivative.exercise_date: Options shall vest at a rate of 25% one year from grant date and monthly thereafter until all shares are fully vested four years from grant date. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 21:42 UTC | Seagen Inc. SGEN · Entity 13956 | GrantIncentive Stock Options (right to buy) · Derivative | 1,333 | $0.00 Strike: $72.64 | $0.00 |
DisclosureSEC source: 0000899243-19-022786 · doc4.xml · derivative · entry 3 LIU JEAN I · CIK 0001241357 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,333 Underlying: Common Stock · 1,333 shares Expires 2029-08-30 F5 · derivative.exercise_date: Options shall vest at a rate of 25% one year from grant date and monthly thereafter until all shares are fully vested four years from grant date. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 21:42 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 18,995 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-022786 · doc4.xml · nonDerivative · entry 1 LIU JEAN I · CIK 0001241357 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,899 F1 · security: These shares represent restricted stock units and will be settled in common stock upon vesting. F2 · date: Shares shall vest at a rate of 25% on each anniversary of the grant date until all shares are fully vested four years from the grant date. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 28, 2019 Filed Aug 30, 2019 16:35 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 6,013 | $73.22 | $440,241.80 |
DisclosureSEC source: 0001203311-19-000040 · edgardoc.xml · nonDerivative · entry 1 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,904 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 20, 2019 Filed Aug 22, 2019 17:47 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 3,716 | $80.00 | $297,280.00 |
DisclosureSEC source: 0001203311-19-000032 · edgardoc.xml · nonDerivative · entry 1 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,917 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 17:42 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 3,716 | $75.00 | $278,700.00 |
DisclosureSEC source: 0001203311-19-000030 · edgardoc.xml · nonDerivative · entry 1 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,633 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 20:56 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 40,523 | $0.00 Strike: $76.86 | $0.00 |
DisclosureSEC source: 0001203311-18-000079 · edgardoc.xml · derivative · entry 3 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,523 Underlying: Common Stock · 40,523 shares Expires 2028-08-30 F4 · derivative.exercise_date: Shares shall vest at a rate of 25% one year from the grant date and monthly thereafter until all shares are fully vested four years from the grant date. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 20:56 UTC | Seagen Inc. SGEN · Entity 13956 | GrantIncentive Stock Option (right to buy) · Derivative | 1,301 | $0.00 Strike: $76.86 | $0.00 |
DisclosureSEC source: 0001203311-18-000079 · edgardoc.xml · derivative · entry 2 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,301 Underlying: Common Stock · 1,301 shares Expires 2028-08-30 F4 · derivative.exercise_date: Shares shall vest at a rate of 25% one year from the grant date and monthly thereafter until all shares are fully vested four years from the grant date. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 20:56 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 17,608 | $0.00 | $0.00 |
DisclosureSEC source: 0001203311-18-000079 · edgardoc.xml · nonDerivative · entry 1 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,349 F1 · security: These shares represent restricted stock units and will be settled in common stock upon vesting. F2 · date: Shares shall vest at a rate of 25% on each anniversary of the grant date until all shares are fully vested four years from the grant date. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 19:37 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 4,123 | $74.23 | $306,057.71 |
DisclosureSEC source: 0001203311-18-000065 · edgardoc.xml · nonDerivative · entry 1 LIU JEAN I · CIK 0001241357 · GC/EVP, Leg Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,741 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| March 20, 2018 Filed Mar 22, 2018 21:34 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-qualified Stock Option (Right to buy) · Derivative | 8,333 | $0.00 Strike: $34.20 | $0.00 |
DisclosureSEC source: 0000899243-18-008414 · doc4.xml · derivative · entry 1 LIU JEAN I · CIK 0001241357 · GC & EVP, Legal Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,333 Underlying: Common Stock · 8,333 shares Expires 2026-05-09 F1 · derivative.exercise_date: On May 9, 2016, the reporting person was granted an option to purchase 8,333 options of common stock. The performance criteria for this grant were met as of March 20, 2018 and the option shall vest in four (4) equal tranches on the first, second, third and fourth anniversaries of March 20, 2018 subject to continuous service with the Company as of each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.